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ABSTRACT
A Physiologically-Based Pharmacokinetic Model for Ertapenem
by
Whitney Forbes
Ertapenem is a carbapenem used to treat a wide range of bacterial infections. What
sets ertapenem apart from other carbapenems is its longer half-life which
implies it need only be administered once daily. We developed a physiologically-
based pharmacokinetic model for the distribution of ertapenem within the body. In
the model, parameters such as human body weight and height, age, organ volumes,
blood flow rates, and partition coefficients of particular tissues are used to examine
the absorption, distribution, metabolism, and excretion of ertapenem. The total and
free blood concentrations found were then compared to experimental data. We then
examined the sensitivity of the total concentration in the blood to body weight, body
height, and age. This analysis allows the possibility of the model being used as a
basis for understanding how differing health conditions might alter the concentration
of ertapenem in the body and hence dosage may need to be adjusted.
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1 INTRODUCTION
Ertapenem is an antibiotic in the carbapenem family which is used to treat a
wide range of antibacterial infections. What sets ertapenem apart from the other
carbapenems is its longer half-life so it only needs to be administered once daily. We
built a mathematical model which shows the concentration of ertapenem as it travels
throughout the body. This project was a result of discussions with East Tennessee
State University’s Quillen College of Medicine and their interest in determining how
much the concentration of ertapenem varied based on body mass index, BMI, in
healthy and unhealthy individuals. We used data from from a study for healthy
young adults to fit our model [8].
This problem is of interest because every antibiotic has a minimum inhibitory
concentration, MIC, level. If the concentration of the antibiotic falls below its MIC
level, the patient may become at risk for developing antibiotic resistance. By studying
the concentration of ertapenem throughout the body based on a patient’s BMI, it
might be possible to determine if a patient could possibly need a smaller or larger
dose depending on if he or she is average weight, underweight, overweight, or obese.
A preliminary model was developed by Manning, et. al. in [7]. We took this
original model and expanded it to examine the free blood concentration levels which
is most important when examining the effectiveness of an antibiotic.
In order to model the distribution of ertapenem throughout the body, we built a
physiologically-based pharmacokinetic (PBPK) model. PBPK models use physiolog-
ical and drug specific constants and parameters [3]. Pharmacokinetics is the study of
the effects the body has on the absorption, distribution, metabolism, and excretion of
10
a drug, also known as ADME. In the following section, we discuss the PBPK model
derivation for a 1 g dose of ertapenem administered intravenously once daily.
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2 MODEL DERIVATION
Figure 1 is a basic schematic of our model. The drug is administered intravenously
such that it goes straight into the blood stream. From the blood stream, it is dis-
tributed throughout the body. The specific compartments we chose to look at are the
adipose, kidneys, and gut and then the rest of the body is grouped in the “other tis-
sues” compartment. We chose to specifically look at the adipose because we wanted
to research how a person’s BMI affects the concentration of the drug throughout the
body, the kidneys because 80% of ertapenem is excreted through the urine, and the
gut because 10% of ertapenem is excreted through the feces [8]. Most PBPK models
also include metabolism. We chose to exclude metabolism from our model because
ertapenem is metabolized mostly in the kidneys [9]. After the drug flows through
a particular compartment, it then returns to the blood stream and the distribution
process is repeated. To build our basic model, we only considered a 24 hour period
since ertapenem is to be administered once daily. Our ODE system calculates the
change in concentration of the drug in each compartment over time (dCtissue
dt
). Table
1 lists the equations which make up our ODE system.
12
Figure 1: Model Schematic
Table 1: ODE System
Adipose dCF
dt
=
QF
(
CBf−CFPF
)
VF
Kidneys dCK
dt
=
QK
(
CBf−CKPK
)
−kUCK
VK
Gut dCG
dt
=
QG
(
CBf−CGPG
)
−kFCG
VG
Other Tissues dCOT
dt
=
QOT
(
CBf−COTPOT
)
VOT
Blood dCBl
dt
=
QF
CF
PF
+QK
CK
PK
+QG
CG
PG
+QOT
COT
POT
+RI−QTotalCBf
VBl
Urine dCUrine
dt
= kUCK
VK
Feces dCFeces
dt
= kFCG
VG
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Ertapenem is highly bound to human plasma proteins. Only the free, unbound,
portion of the drug actually saturates the tissues and can be excreted. Since only the
free, or unbound, concentration of the drug is considered to be medicinally effective,
we chose to look at both the total concentration and the free concentration in the
blood. Also, the free concentration is the part of the concentration which can effec-
tively be taken up by the tissues. This is also why we modeled the concentration in
the tissues using the free concentration. The free concentration in the blood, CBf , is
calculated from the total concentration in the blood using the equation
CBf =
CBl −Bm −Kd +
√
(Bm +Kd − CBl)2 + 4(Kd · CBl)
2
.
This equation for free concentration and the estimation for Bm and Kd are explained
in detail in the next chapter.
The change in the amount of drug in a compartment at time t is represented by
dAtissue
dt
= Qtissue
(
CBf − Ctissue
Ptissue
)
.
In our model, the amount of ertapenem in a compartment is measured in grams.
The amount of drug in a particular compartment can also be represented as the
concentration in the compartment ( g
mL
) multiplied by the compartment’s volume
(mL). That is,
Atissue = Ctissue · Vtissue.
14
Therefore, at time t the change in concentration is
dCtissue
dt
=
dAtissueVtissue
dt
=
1
Vtissue
· dAtissue
dt
=
Qtissue
(
CBf − CtissuePtissue
)
Vtissue
.
Figure 2 is the same schematic as before but this one includes a break down
of all the mass balance equations in the ODE system. Each tissue compartment
has a concentration coming in and a concentration going out. The kidney and gut
compartments also have the portion of concentration being excreted.
Figure 2: Model Schematic with Mass Balance Equations
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As illustrated in Table 2, each of the Qi terms represent the blood flow for the
given tissue compartment, Ci represents the concentration, Vi represents the volume,
Pi represents the partition coefficient, ki represents the clearance rate, and RI is the
rate of infusion. The rate of infusion is given by
RI =

D
TI
if t ≤ TI
0 if t > TI .
where D is the dosage, 1 g, and TI is the length of time of infusion, 30 minutes. All of
these terms are constants except Ci and RI . The blood flow rates and tissue volumes
are strictly physiological, the partition coefficients are physiological and drug specific,
and the clearance rates are drug specific.
Table 2: Definitions of Model Variables and Parameters
Symbol Description Units
Ci Concentration of ertapenem in tissue i
g
mL
AUrine Amount of ertapenem in urine g
AFeces Amount of ertapenem in feces g
Vi Volume of tissue i mL
Qi Blood flow rate in tissue i
mL
hr
t Time hr
Pi Tissue:blood partition coefficient for tissue i unitless
BW Body Weight kg
BH Body Height m
AGE Age years
RI Rate of Infusion
g
hr
D Dosage g
TI Length of time of infusion hr
kU Urine clearance constant
mL
hour
kF Feces clearance constant
mL
hour
In reference [4], the total blood flow rate was calculated based on body weight
16
using
QTotal = 60 · (235 ·BW )0.71 .
Each of the blood flow rates for the tissue compartments were calculated based on
their fraction of the total blood flow rate. In order to determine the fraction of the
total blood flow rate for the “other tissues” compartment, we subtracted the sum of
the fraction of total blood flow for the adipose, kidney, and gut compartments from
the total blood flow. The fraction of the total blood flow rate for the adipose tissue,
kidneys, and gut were found in references [2] and [10],
QF = 0.052 ·QTotal
QK = 0.19 ·QTotal
QG = 0.17 ·QTotal
QOT = QTotal − (QF +QK +QG)
The volume of the blood and the individual tissue compartments was calculated
based on body weight, body height, and age. The volume for the “other tissues”
compartment was calculated by subtracting the sum of the volumes for the blood,
adipose, kidneys, and gut from the body weight in grams. We were able to do so
because we assumed BW = V olume · 1kg
1L
since the densities of most soft tissues have
17
a value between 0.95 and 1.05 [5]. In references [6], [10], and [13], we have equations
VBl =
13.1 ·BH · 100 + 18.05 ·BW − 480
0.5723
VF = (1.36 · BW
BH
− 42) · 1000
VK = 2 · (5.04 + 2.53 · AGE + 1.31 ·BW + 1.36 ·BH · 100− 255.7)
VG = (0.0171 ·BW ) · 1000
VOT = BW · 1000− (VBl + VF + VK + VG)
The partition coefficients for the individual tissue compartments represent the
tissue’s solubility. They determine the portion of concentration that can flow from
each tissue back into the blood. For example, PF = 1.946845001 means 1 mL of
adipose tissue can hold 1.946845001 times as much ertapenem as 1 mL of blood. The
equation we used to estimate the partition coefficients includes both physiological and
drug specific parameters.
Pt =
[So ·Nt] + [(Sw · 0.7Pt) + (So · 0.3Pt)] + [Sw ·Wt]
[So ·Nb] + [(Sw · 0.7Pb) + (So · 0.3Pb)] + [Sw ·Wb]
where Sw is the solubility of the chemical in water and So is the solubility of the
chemical in n-octanol [12]. Nt, Pt, and Wt are the fraction of tissue volume that
is neutral lipids, phospholipids, and water, respectively; whereas, Nb, Pb, and Wb
are the fraction of blood volume that is neutral lipids, phospholipids, and water. For
ertapenem, Sw = 0.069230349
mol
m3
and So = Kow ·Sw where Kow = 1.66 is the solubility
of ertapenem in n-octanol:water [14]. Thus, using the equation, we calculated the
18
following:
PF = 1.946845001
PK = 1.047008099
PG = 0.896409391
POT = 1.012441852
The clearance rates for the kidneys and the gut are represented by kU and kF .
Both of these parameters are drug specific. We needed to estimate both parameters
such that the excretion of ertapenem through the urine was approximately 80% and
through the feces was approximately 10%. This estimation will be discussed in the
next chapter.
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3 PARAMETER ESTIMATION
In chapter 2, we mentioned a few parameters which needed to be estimated. In
this chapter, we will discuss those parameters and the methods used to estimate them.
3.1 Splitting the Blood Compartment
Every antibiotic has a minimum inhibitory concentration, MIC, level. If the con-
centration of the drug in the blood falls below its MIC level, the patient becomes
at risk of developing antibiotic resistant bacteria. Since only the free concentration
of the drug is considered to be medicinally effective, we decided to look at both the
total and free concentration of ertapenem in the blood. In order to do so, we had to
determine how much of the total concentration was free and how much was bound.
Ertapenem is highly bound to human plasma proteins. In healthy young adults, the
binding decreases as the total concentration in the blood increases. It is approxi-
mately 95% bound when the total concentration in the blood is less than 0.0001 g
mL
but decreases to 85% bound when the concentration reaches 0.0003 g
mL
[8]. The total
concentration in the blood is given by
Total = Free+Bound.
In our model, we denoted the total concentration in the blood by CBl, the free con-
centration by CBf , and the bound concentration by CBound. The bound concentration
in the blood can be modeled using a nonlinear Michaelis-Menten equation
CBound =
BmCBf
Kd + CBf
20
where Bm is the blood receptor content and Kd is the dissociation constant [11]. By
substituting the equation for the bound concentration into the equation for the total
concentration, we have
CBl = CBf +
BmCBf
Kd + CBf
. (1)
This allowed us to study the total and free concentrations without directly calculat-
ing the bound concentration. By simple algebraic manipulation and the quadratic
formula, we were able to obtain the following equation for the free concentration
CBf =
CBl −Bm −Kd +
√
(Bm +Kd − CBl)2 + 4KdCBl
2
. (2)
This equation gives the free concentration in terms of CBl, Bm, and Kd.
After obtaining the equation for the free concentration in the blood, we had to
determine a way to estimate Bm and Kd. We found clinical data that gave both the
total and free concentrations in the blood at corresponding times after infusion. The
data values are listed in Table 3 and can be seen in Figure 3. We were able to use
this data and equation (1) to estimate Bm and Kd.
Table 3: Clinical Data for the Total and Free Concentrations in the Blood [9]
Time (hours) Total Concentration (mcg
mL
) Free Concentration (mcg
mL
)
0.1 96.5402 6.4626
0.25 160.2984 15.4753
4 50.5676 2.7021
6 30.4746 1.5832
8 20.5561 1.0984
12 10.4683 0.4221
18 3.6985 0.145
21
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Figure 3: Clinical Data for the Total and Free Concentrations in the Blood
The values of CBl and CBf are from clinical data [9]. In Matlab, we used
fminsearch, a built-in Matlab optimization algorithm, in order to estimate the values
of Bm and Kd such that the cost function
J(Bm, Kd) =
∑
(CBl,data − CBl,pred(Bm, Kd))2 +
∑
(CBf,data − CBf,pred(Bm, Kd))2
is minimized where CBl,pred(Bm, Kd) is the value of CBl using equation (1) and
CBf,pred(Bm, Kd) is the value of CBf using equation (2) with given values of Bm
and Kd. We started with an initial guess and obtained optimal values of Bm =
22
259.7319mcg
mL
andKd = 12.2480
mcg
mL
with the cost function minimized to J = 7.6216
(
mcg
mL
)2
.
In some cases standard error and confidence intervals are used, but we have chosen to
use point estimates in this paper. Figure 4 shows the approximation using equation
(1) with the optimal values for Bm and Kd against the clinical data for the total
concentration in the blood. Figure 5 shows the same for the free concentration in the
blood.
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Figure 4: Clinical Data vs Estimated Values for the Total Concentration in the Blood
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Figure 5: Clinical Data vs Estimated Values for the Free Concentration in the Blood
3.2 Estimating kU and kF
We used the equations
dCUrine
dt
=
kUCK
VK
dCFeces
dt
=
kFCG
VG
to describe the excretion of ertapenem in the urine and feces. The parameters kU and
kF are the clearance rates for the kidneys and the gut in
mL
hour
and are drug specific.
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From literature, we knew approximately 80% of ertapenem is excreted in the urine
and approximately 10% in the feces. Thus, since they are drug specific, we were
able to estimate kU and kF by choosing values such that the amount of ertapenem,
Aurine = Curine · VK , in the urine after 24 hours was approximately 0.8g (80% of a 1g
dose) and the amount in the feces was approximately 0.1g (10% of a 1g dose). Doing
so, we found the values kU = 55, 000
mL
hour
and kF = 8, 000
mL
hour
which gave us 79.63%
excreted in the urine and 18.24% excreted in the feces after 24 hours. Although more
than 10% was excreted in the feces, the model did not incorporate metabolism. We
believe that if the model included metabolism, then we could have further reduced
the error in the feces output. However, as is, the model for total blood concentration
matches the data in the literature well (see Figure 6 in chapter 4).
3.3 Estimation for the Model During Infusion
We had difficulties getting the peak of the total and free concentrations in the
blood in our model to match that of the clinical data. This was due to the model
excreting the drug too quickly. Since this is a model, it does not automatically
know that a drug will not be immediately excreted within the 30 minute infusion
time. To control this, rather than having the proportion of the free concentration
be partially determined by the amount of drug excreted, we set the excretion in the
urine and the feces equal to zero during the infusion (first 30 minutes) and estimated
the proportion of the free concentration being distributed throughout the body. We
did so by calculating an inverse problem. In the model, during infusion, instead of
assuming the outflow from the blood compartment was the entire free portion of the
25
drug, we instead assumed that the outflow from the blood to the tissue compartments
was αCBf where α was the parameter we were estimating. In Matlab, we used the
fminsearch optimization algorithm again to estimate α such that the cost function,
in equation (2), was minimized. For the inverse problem, we used
J(α) =
∑
(CBl,data − CBl,pred(α))2 +
∑
(CBf,data − CBf,pred(α))2. (3)
We started with an initial guess and obtained an optimal value of α = 0.2789 with
the cost function minimized to J = 52.7576
(
mcg
mL
)2
.
After estimating all of the parameters from this chapter, we were able to complete
our basic model for a young adult male with average weight and height. Having a
complete basic model meant we could start performing simulations. We ran simu-
lations for males and females who are underweight, average weight, overweight, and
obese for both a one day, 24 hour, period and a 3 day, 72 hour, period. The details
of these simulations are the topic of the next chapter.
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4 SIMULATIONS
We compared our model based on a young adult male with average body weight
and height, age 32 years weighing 72 kg (159 lbs) and a height of 1.778 m (70 in), to
clinical data [1] [15]. When compared to the clinical data, the total concentration in
the blood for our model had an error of 4.22% (Figure 6) and the free concentration
had an error of 2.12% (Figure 7). After building this basic model, we then used it to
run simulations by varying the parameters body weight and body height.
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Figure 6: Total Concentration in the Blood
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Figure 7: Free Concentration in the Blood
4.1 Male BMI
In order to study the effects of BMI on the concentration of ertapenem throughout
the body, we took our basic model for a young male of average weight and height and
changed only the weight to show the difference in the concentration based upon BMI
classification of a young adult male of average height. In Table 4, the weights used
corresponding to underweight, average weight, overweight, and obese are listed.
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Table 4: Weights (Males) [15]
Weight Description Numerical Weight (kg)
Underweight 55
Average Weight 72
Overweight 85
Obese 106
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Figure 8: Total Concentration in the Blood (Male BMI)
Figure 8 shows a comparison of the total concentration in the blood based on
BMI. Between hours 0.5 and approximately 10, the total concentration in the blood
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is lowest for obese. After that, the total concentration in the blood is highest for
obese. The concentration for underweight is the exact opposite. More important
than the total concentration in the blood though is the free concentration which can
be seen in Figure 9 below.
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Figure 9: Free Concentration in the Blood (Male BMI)
The free concentration cannot fall below the MIC level so it is important to look
at the lowest values of the concentration. This can be seen below in Figure 10 which
is the same as Figure 9 but it only shows the concentration for hours 20 to 24.
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Figure 10: Free Concentration in the Blood for Hours 20 to 24(Male BMI)
In Figure 10, underweight males have the lowest concentration at approximately
0.0565mcg
mL
. The lowest concentration for average weight is approximately 0.0916mcg
mL
,
overweight is approximately 0.1207mcg
mL
, and obese is approximately 0.1569mcg
mL
. Thus
implying BMI does have an effect on concentration.
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Figure 11: Amount of Dose in the Adipose Tissue (Male BMI)
Figure 11 is the amount of the 1 g dose in the adipose tissue, or fat tissue. The
curve for underweight barely rises above zero which makes sense since an underweight
person has less fatty tissue; therefore, there is less tissue volume for the drug to absorb.
Applying the same theory, it makes sense that the amount of ertapenem in the adipose
tissue is greatest in those who are obese because they have the most fatty tissue.
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4.2 Female BMI
Just as we did for male BMI, we changed the weights to correspond to females
who are underweight, average weight, overweight, and obese. The weights used can
be found in Table 5. We kept the age at 32 years but changed the average weight
to 61 kg (134 lbs) and height to 1.62 m (64 in) [1] [15]. We also had to change
the equations used for the volumes of the tissues. In references [2], [6], [10], the
equations for volume were
VBl =
35.5 ·BH · 100 + 2.27 ·BW − 3382
0.6178
VF = (1.61
BW
BH
− 38.3) · 1000
VK = 2 · (5.04 · 2 + 2.53 · AGE + 1.31 ·BW + 1.36 ·BH · 100− 255.7)
VG = (0.0171 ·BW ) · 1000
VOT = BW · 1000− (VB + VF + VK + VG).
Table 5: Weights (Females) [15]
Weight Description Numerical Weight (kg)
Underweight 44
Average Weight 61
Overweight 72
Obese 99
The volumes for males are greater than the volumes for females in all the compart-
ments except for the adipose tissue. Also note that all of the volumes for males and
females increase as body weight increases except for the volume of the other tissues
in females which actually decreases as body weight increases. This is due to the large
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increases in the volume of the adipose tissue as body weight increases.
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Figure 12: Total Concentration in the Blood (Female BMI)
Figure 12 shows the total concentration of ertapenem in the blood. Just like the
total concentration in the blood for males, underweight females starts out having the
highest concentration and obese females the lowest. However, instead of switching at
approximately hour 10, the switch occurs at approximately hour 13. This difference
will affect the other compartments as well.
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Figure 13: Free Concentration in the Blood (Female BMI)
The peak for the free concentration in the blood for underweight males was at
approximately 19.4899mcg
mL
. However, for the females it is higher at approximately
29.9616mcg
mL
. The peak for average weight males was approximately 15.4687mcg
mL
and for
average weight females it was 27.6066mcg
mL
. Overweight males had a peak at 13.5064mcg
mL
and overweight females had a peak at 26.4586mcg
mL
. Obese males and females had the
lowest peaks at 11.2016mcg
mL
for males and 24.2995mcg
mL
for females.
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Figure 14: Free Concentration in the Blood Hours 20 to 24 (Female BMI)
By looking at Figure 14, you can see the minimum concentration for underweight
females is approximately 0.0430mcg
mL
, average weight is approximately 0.0880mcg
mL
, over-
weight is approximately 0.1134mcg
mL
, and obese is approximately 0.1478mcg
mL
. So for un-
derweight, average weight, overweight, and obese females, the peak concentrations are
higher but the minimum concentrations are lower compared to underweight, average
weight, overweight, and obese males.
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Figure 15: Amount of Dose in the Adipose Tissue (Female BMI)
When looking at the peak for the amount of ertapenem in the adipose tissue, the
amount is approximately 0.0022 mcg for underweight males, 0.0897 mcg for aver-
age weight males, 0.1199 mcg for overweight males, and 0.1520 mcg for obese males.
However, the peaks for the females are higher at approximately 0.0661 mcg for un-
derweight, 0.1425 mcg for average weight, 0.1710 mcg for overweight, and 0.2201 mcg
for obese. As for the minimum amounts, the minimum for males is approximately
0.0000 mcg for underweight, 0.0032 mcg for average weight, 0.0084 mcg for over-
weight, and 0.0207 mcg for obese. Again, the amounts for the females are higher
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with minimums at approximately 0.0010 mcg for underweight, 0.0074 mcg for av-
erage weight, 0.0158 mcg for overweight, and 0.0399 mcg for obese. The increased
amount of ertapenem in the adipose tissue of females is due to the larger volume of
adipose tissue. A greater amount staying in the adipose tissue causes the concentra-
tion in the blood to be lower has shown above.
4.3 Male BMI - 3 days
The next step we took was studying the concentration when a patient receives a
1 g dose of ertapenem every 24 hours over a period of three days. We used the exact
same equations but instead of ending after 24 hours, the model repeats the process
for two more days. The only difference is at the beginning of the second and third
day. Instead of starting with 0 g of ertapenem at the time of infusion, the model
starts out with the concentration of drug still in the body from the previous dose.
As mentioned before, an antibiotic must stay above its MIC level to prevent the
risk of a patient developing antibiotic resistant bacteria, but it is also dangerous if the
concentration stays too high for too long. Such an event can be toxic to the patient.
Figure 16 shows the total concentration in the blood over the three day period and
Figure 17 shows the free concentration.
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Figure 16: Total Concentration in the Blood (Male BMI - 3 Days)
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Figure 17: Free Concentration in the Blood (Male BMI - 3 Days)
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Figure 18: Free Concentration in the Blood Hours 20 to 24 (Male BMI - 3 Days)
Figure 18 above shows the free concentration in the blood over the last four hours
of day one and Figure 19 below shows the free concentration in the blood over the last
four hours on the third day. For hours 20 to 24, the free concentration in the blood for
underweight starts at approximately 0.1205mcg
mL
and ends at approximately 0.0565mcg
mL
.
The values for hours 68 to 72 are approximately 0.1209mcg
mL
at hour 68 and 0.0572mcg
mL
at hour 72. For average weight over the hours 20 to 24, the free concentration starts
at approximately 0.1733mcg
mL
and ends at approximately 0.0916mcg
mL
. The values are
approximately 0.1757mcg
mL
for hour 68 and 0.0934mcg
mL
for hour 72. For overweight
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over the hours 20 to 24, the free concentration starts at approximately 0.2083mcg
mL
and ends at approximately 0.0.1207mcg
mL
. However, for hours 68 to 72, the concentra-
tion starts at approximately 0.2143mcg
mL
and ends at approximately 0.1248mcg
mL
. The
difference between hours 20 to 24 and 68 to 72 are greatest for obese. For hours
20 to 24, the concentration starts at approximately 0.2453mcg
mL
and ends at approxi-
mately 0.1569mcg
mL
, and for hours 68 to 72, the concentration starts at approximately
0.2606mcg
mL
and ends at approximately 0.1670mcg
mL
. As weight increases, the difference
between the concentration at hour 24 and 72 increases.
68 68.5 69 69.5 70 70.5 71 71.5 72
0
0.05
0.1
0.15
0.2
0.25
0.3
Time (hours)
Fr
ee
 C
on
ce
nt
ra
tio
n 
in
 B
lo
od
 
 
Underweight
Average BW
Overweight
Obese
Figure 19: Free Concentration in the Blood Hours 68 to 72 (Male BMI - 3 Days)
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Figure 20: Amount of Dose in the Adipose Tissue (Male BMI - 3 Days)
The peaks right after infusion are higher on the second and third day, but the
minimum amounts at the end of each 24 hour period are approximately the same.
4.4 Female BMI - 3 days
This is the same as the previous simulation but it is for females rather than males.
It uses the changes described at the beginning of sections 4.2 and 4.3. Figure 21 shows
the total concentration in the blood over the three day period and Figure 22 shows
the free concentration.
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Figure 21: Total Concentration in the Blood (Female BMI - 3 Days)
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Figure 22: Free Concentration in the Blood (Female BMI - 3 Days)
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Figure 23: Free Concentration in the Blood Hours 20 to 24 (Female BMI - 3 Days)
Figure 23 above shows the free concentration in the blood over the last four hours
of day one and Figure 24 below shows the free concentration in the blood over the last
four hours on the third day. For hours 20 to 24, the free concentration in the blood for
underweight starts at approximately 0.0971mcg
mL
and ends at approximately 0.0430mcg
mL
.
The values for hours 68 to 72 are approximately 0.0.0981mcg
mL
at hour 68 and 0.0436mcg
mL
at hour 72. For average weight over the hours 20 to 24, the free concentration starts
at approximately 0.1597mcg
mL
and ends at approximately 0.0880mcg
mL
. The values are
approximately 0.1646mcg
mL
for hour 68 and 0.0902mcg
mL
for hour72. For overweight over
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the hours 20 to 24, the free concentration starts at approximately 0.1868mcg
mL
and
ends at approximately 0.1134mcg
mL
. However, for hours 68 to 72, the concentration
starts at approximately 0.1954mcg
mL
and ends at approximately 0.1187mcg
mL
. The differ-
ence between hours 20 to 24 and 68 to 72 are greatest for obese. For hours 20 to
24, the concentration starts at approximately 0.2122mcg
mL
and ends at approximately
0.1478mcg
mL
, and for hours 68 to 72, the concentration is higher starting at approxi-
mately 0.2351mcg
mL
and ending at approximately 0.1639mcg
mL
. The amount of difference
between hours 24 and 72 are higher for females, but the values of the concentrations
are all slightly higher for males.
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Figure 24: Free Concentration in the Blood Hours 68 to 72 (Female BMI - 3 Days)
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Figure 25: Amount of Dose in the Adipose Tissue (Female BMI - 3 Days)
Just as in the model for the males, the peaks right after infusion are higher on the
second and third day, but the minimum amounts at the end of each 24 hour period
are approximately the same.
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5 SENSITIVITY ANALYSIS
PBPK models rely on physiological constants such as blood flow rates and tissue
volumes. These constants also have terms they rely on. The blood flow rates for the
individual tissue compartments were calculated as fractions of the total blood flow,
but the total blood flow is calculated based on body weight. The individual tissue
volumes depend on body height, body weight, and age. Specifically, the volume of
the gut depends on body weight; the volume of the blood and adipose tissue depends
on body height and weight; the volume of the kidneys depends on body height, body
weight, and age; and the volume for the “other tissues” compartment depends on
body weight and the volumes of the other compartments. PBPK models also rely on
drug specific parameters such as the clearance rate of ertapenem through the kidneys
and gut, kU and kF respectively. Therefore, we tested our basic model’s sensitivity
to the parameters body height, body weight, age, kU , and kF .
Sensitivity analysis allowed us to determine if slight changes in those parameters
would have a large affect on the concentrations produced by our model. If a particular
parameter is considered to be sensitive, it is crucial that the value used in the model
is accurate in order for the model to be reliable. The sensitivity of a state variable
to the parameters is determined by calculating ∂Ctissue∂qj
for each state variable Ctissue
and each parameter qj where
Ctissue = {CF , CK , CG, COT , CBl} and q = {BH,BW,AGE, kU , kF}.
To calculate the relative sensitivity which determines which parameter has the
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most effect on each state variable, we used the modified L2 norm∣∣∣∣∣∣∣∣∂Ctissue∂qj
∣∣∣∣∣∣∣∣
2
=
[
1
tf − t0
∫ tf
t0
(
∂Ctissue
∂qj
)2
dt
] 1
2
qj
maxCtissue
which normalizes the sensitivity values by removing the units. Figure 26 shows the
relative sensitivities of body height, body weight, age, kU , and kF for the concentration
of each compartment.
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Figure 26: Relative Sensitivities
The adipose tissue compartment is most sensitive to body weight and height
which is understandable considering a person’s body weight and height extremely
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effects the volume of the adipose tissue. Neither the kidney nor gut compartments
are very sensitive to any of the parameters. The sensitivity for body weight and
height is slightly raised for the “other tissues” compartment. This is because the
volume and blood flow rate of the “other tissues” compartment is dependent on the
volumes and blood flow rates of the other compartments. Therefore, since the adipose
is so sharply sensitive to body weight and height, that sensitivity is passed on to the
“other tissues” compartment.
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6 CONCLUSIONS
We built a physiologically-based pharmacokinetic model for the antibiotic er-
tapenem. In order to do so, we had to use both physiological constants and drug
specific parameters where some of the parameters had to be estimated. We were
able to build a basic model that only has a 4.25% error when compared to clinical
data. After completing the basic model, we were able to study the affects of body
mass index and gender on the concentration of ertapenem throughout the body. We
looked at one 1g dose over a 24 hour period and three 1g doses given every 24 hours
over a 72 hour period for both males and females. We saw that the free concentration
in the blood, which is the part that is considered to be medicinally effective, is higher
for males than females and it is slightly higher in overweight and obese patients at
the end of 72 hours when compared to the concentration at the end of 24 hours.
In the future, this model can be used to study the minimum inhibitory concen-
tration level. It can also be expanded to study the effects health conditions may have
on the concentration throughout the body. Health conditions which effect the renal
system for example might change the concentration due to the drug not being able
to be excreted through the feces properly.
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